Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Medical School

Duke University School of Medicine

1985, Durham, NC

Internship

Duke University Hospital

1986, Durham, NC

Residency

Duke University Hospital

1988, Durham, NC

Fellowship

Boston Children's Hospital

1991, Boston, MA

Fellowship

Clinical Research/Pediatric Gastroenterology and Nutrition

Boston Combined Residency Program (BCRP)

1991, Boston, MA

Certifications

  • American Board of Pediatrics (Gastroenterology)
  • American Board of Pediatrics (General)

Professional History

Athos Bousvaros MD, MPH is a pediatric gastroenterologist who has worked at Boston Children’s Hospital for over 25 years.  He completed his undergraduate degree at Williams College, his medical degree and residency at Duke University, and his gastroenterology fellowship at Boston Children's Hospital, Massachusetts General Hospital, and Harvard Medical School.  As Associate Director of the Inflammatory Bowel Disease program at Boston Children's Hospital, he spends much of his time treating complex cases of Crohn’s disease and ulcerative colitis referred from across the country.  His research interests include identifying the cause of IBD by studying the intestinal microbiome, developing new therapies for IBD, and examining the immune response of IBD patients to immunizations.  He has over 100 original and review publications in medical literature. 

He has served as Chair of the Chapter Medical Advisory Committee of the New England Crohn’s and Colitis Foundation of America and Chair of the CCFA Pediatric Affairs committee.  He has also served as President of the North American Society for Pediatric GI and Nutrition (NASPGHAN), where he helped lead a campaign to promote child safety by getting high powered magnets out of the hands of toddlers. When not busy caring for patients or doing research, he enjoys developing patient education materials for children with chronic illness.  These include the medical comics: “Pete Learns All About Crohn’s and Colitis” (with the CCFA), “Amy Goes Gluten Free,” “JD Shapes Up,” and “Sophie’s Science Project.” He has also co-authored the NASPGHAN book “Your Child with Inflammatory Bowel Disease.” 

Media

Caregiver Profile

Meet Dr. Athos Bousvaros

Publications

  1. Clinical outcomes of maintenance therapy with sulfasalazine compared to 5-aminosalicylates in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2025 Apr 10. View Abstract

  2. HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. Am J Gastroenterol. 2025 May 01; 120(5):1076-1086. View Abstract

  3. HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. Am J Gastroenterol. 2024 Oct 18. View Abstract

  4. Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease. Inflamm Bowel Dis. 2024 Oct 17. View Abstract

  5. Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 Oct 16. View Abstract

  6. Cytomegalovirus Colitis in a Patient With Ulcerative Colitis With Loss of Corticosteroid Response Upon Upadacitinib Initiation. Gastroenterol Hepatol (N Y). 2024 Oct; 20(9):546-549. View Abstract

  7. Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 09 03; 30(9):1443-1453. View Abstract

  8. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after fecal microbiota transplant in inflammatory bowel disease. Sci Rep. 2024 08 06; 14(1):18188. View Abstract

  9. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease. Am J Gastroenterol. 2024 06 01; 119(6):1110-1116. View Abstract

  10. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024 Jul; 22(7):1475-1486.e4. View Abstract

  11. Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024 Apr; 78(4):871-877. View Abstract

  12. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024 02; 78(2):261-271. View Abstract

  13. Collaborative Registries for Pediatric Crohn's Disease: A Leap Forward or More of the Same? Am J Gastroenterol. 2024 03 01; 119(3):450-451. View Abstract

  14. Comparing Gastrointestinal Endoscopy Findings in Children with Autism, Developmental Delay, or Typical Development. J Pediatr. 2024 01; 264:113737. View Abstract

  15. Endoscopy of the Ileal Pouch Anal Anastomosis. J Pediatr Gastroenterol Nutr. 2023 12 01; 77(6):691-694. View Abstract

  16. Reply. Gastroenterology. 2023 Nov; 165(5):1308. View Abstract

  17. Helicobacter pylori Antimicrobial Resistance Using Next-Generation Sequencing in Stool Samples in a Pediatric Population. J Pediatr Gastroenterol Nutr. 2023 11 01; 77(5):623-627. View Abstract

  18. Treatment of Genital Crohn's Disease With Upadacitinib in a Male Child: A Case Report. Gastroenterol Hepatol (N Y). 2023 Jul; 19(7):401-403. View Abstract

  19. Efficacy and Safety of Tacrolimus or Infliximab Therapy in Children and Young Adults With Acute Severe Colitis. J Pediatr Gastroenterol Nutr. 2023 08 01; 77(2):222-227. View Abstract

  20. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial. Gastroenterology. 2023 07; 165(1):149-161.e7. View Abstract

  21. Helicobacter pylori Antimicrobial Resistance in a Pediatric Population From the New England Region of the United States. Clin Gastroenterol Hepatol. 2023 12; 21(13):3458-3460.e2. View Abstract

  22. Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 03 01; 29(3):483-486. View Abstract

  23. How to Write an Effective Letter of Medical Necessity. J Pediatr Gastroenterol Nutr. 2023 04 01; 76(4):407-409. View Abstract

  24. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after Fecal Microbiota Transplant in Inflammatory Bowel Disease. medRxiv. 2023 Feb 01. View Abstract

  25. Efficacy and Safety of Sulfasalazine Suspension in Children With Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2023 04 01; 76(4):460-467. View Abstract

  26. Development and Validation of the TUMMY-UC: A Patient-Reported Outcome for Pediatric Ulcerative Colitis. Gastroenterology. 2023 04; 164(4):610-618.e4. View Abstract

  27. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Inflamm Bowel Dis. 2022 10 03; 28(10):1497-1505. View Abstract

  28. Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease. Am J Gastroenterol. 2023 01 01; 118(1):129-137. View Abstract

  29. Clinical Phenotypes and Outcomes in Monogenic Versus Non-monogenic Very Early Onset Inflammatory Bowel Disease. J Crohns Colitis. 2022 Sep 08; 16(9):1380-1396. View Abstract

  30. Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr. 2022 10 01; 75(4):418-422. View Abstract

  31. Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2022 03 01; 117(3):462-469. View Abstract

  32. Lessons From a Quality Improvement Project to Standardize the Process of Gastric Biopsy Culture for Helicobacter pylori. JPGN Rep. 2021 Nov; 2(4):e116. View Abstract

  33. Agreement on Symptoms Between Children With Ulcerative Colitis and Their Caregivers: Towards Developing the TUMMY-UC. J Pediatr Gastroenterol Nutr. 2021 08 01; 73(2):e35-e38. View Abstract

  34. Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease. Gastroenterology. 2020 08; 159(2):591-608.e10. View Abstract

  35. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis. 2020 05 12; 26(6):820-842. View Abstract

  36. The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease. Gastroenterol Rep (Oxf). 2020 Oct; 8(5):404-406. View Abstract

  37. Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn's Disease Cohort. Inflamm Bowel Dis. 2019 11 14; 25(12):1927-1938. View Abstract

  38. Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease. PLoS One. 2019; 14(10):e0222952. View Abstract

  39. The pharmacotherapeutic management of pediatric Crohn's disease. Expert Opin Pharmacother. 2019 Dec; 20(17):2161-2168. View Abstract

  40. Natural history of children with mild Crohn's disease. World J Gastroenterol. 2019 08 14; 25(30):4235-4245. View Abstract

  41. Commentary: Monitoring Thiopurine Efficacy Without Levels: Is It a Good Idea? J Pediatr Gastroenterol Nutr. 2019 07; 69(1):1-2. View Abstract

  42. Microscopic/"Backwash" Ileitis and Its Association With Colonic Disease in New Onset Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2019 06; 68(6):835-840. View Abstract

  43. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019 05 16; 25(Suppl 2):S40-S47. View Abstract

  44. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut. 2020 01; 69(1):32-41. View Abstract

  45. Microscopic / "Backwash" Ileitis and its Association with Colonic Disease in New Onset Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2019 Jan 21. View Abstract

  46. Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBD. Inflamm Bowel Dis. 2019 01 01; 25(1):27-32. View Abstract

  47. Reducing Redundant Anaerobic Therapy Through Spaced Education and Antimicrobial Stewardship Interventions. J Pediatric Infect Dis Soc. 2018 Dec 03; 7(4):317-322. View Abstract

  48. Mucosal Gene Expression in Pediatric and Adult Patients With Ulcerative Colitis Permits Modeling of Ideal Biopsy Collection Strategy for Transcriptomic Analysis. Inflamm Bowel Dis. 2018 11 29; 24(12):2565-2578. View Abstract

  49. Curved planar reformatting and convolutional neural network-based segmentation of the small bowel for visualization and quantitative assessment of pediatric Crohn's disease from MRI. J Magn Reson Imaging. 2019 06; 49(6):1565-1576. View Abstract

  50. The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 05 18; 24(6):1344-1351. View Abstract

  51. Educational needs in the diagnosis and management of pediatric functional constipation: a US survey of specialist and primary care clinicians. Postgrad Med. 2018 May; 130(4):428-435. View Abstract

  52. Commentary: Button Batteries in Fidget Spinners: Is It Time to Push the "Panic Button"? J Pediatr Gastroenterol Nutr. 2018 04; 66(4):557-558. View Abstract

  53. Biologics Delay Progression of Crohn's Disease, but Not Early Surgery, in Children. Clin Gastroenterol Hepatol. 2018 09; 16(9):1467-1473. View Abstract

  54. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. Gut. 2019 02; 68(2):239-247. View Abstract

  55. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab. J Pediatr Surg. 2018 Jul; 53(7):1330-1333. View Abstract

  56. Enhanced TH17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD. Inflamm Bowel Dis. 2017 11; 23(11):1950-1961. View Abstract

  57. Human RELA haploinsufficiency results in autosomal-dominant chronic mucocutaneous ulceration. J Exp Med. 2017 Jul 03; 214(7):1937-1947. View Abstract

  58. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol. 2017 May 14; 23(18):3322-3329. View Abstract

  59. Outcomes From Pediatric Gastroenterology Maintenance of Certification Using Web-based Modules. J Pediatr Gastroenterol Nutr. 2017 05; 64(5):671-678. View Abstract

  60. From "Jarts" to "Zen Magnets": Protecting Our Children from Dangerous Toys. J Pediatr. 2017 07; 186:6-7. View Abstract

  61. O-011 Low-dose IL-2 Administration Expands Human Regulatory T Cells in Patients with UC and Humanized Mice and Protects Against Experimental Colitis. Inflamm Bowel Dis. 2017 Feb; 23 Suppl 1:S4. View Abstract

  62. Effect of Psychotherapy on Health Care Utilization in Children With Inflammatory Bowel Disease and Depression. J Pediatr Gastroenterol Nutr. 2016 12; 63(6):658-664. View Abstract

  63. Interleukin 1ß Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency. Gastroenterology. 2016 12; 151(6):1100-1104. View Abstract

  64. Postoperative Complications in Children With Crohn Disease Treated With Infliximab. J Pediatr Gastroenterol Nutr. 2016 09; 63(3):352-6. View Abstract

  65. Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents. J Pediatr. 2016 Nov; 178:227-232. View Abstract

  66. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-a Inhibitors. J Pediatr Gastroenterol Nutr. 2016 07; 63(1):130-55. View Abstract

  67. O-017 YI Inflammatory Versus Non-inflammatory Predictors of Specific Depressive Symptoms in a Large Pediatric Cohort with IBD. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S6. View Abstract

  68. Prevalence of Inflammatory Bowel Disease Among Patients with Autism Spectrum Disorders. Inflamm Bowel Dis. 2015 Oct; 21(10):2281-8. View Abstract

  69. Thalidomide Treatment of Pediatric Ulcerative Colitis: A New Use for an Old Drug. Inflamm Bowel Dis. 2015 Aug; 21(8):1750-1. View Abstract

  70. Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1321-8. View Abstract

  71. Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. J Pediatr. 2015 Sep; 167(3):527-32.e1-3. View Abstract

  72. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1748-56. View Abstract

  73. Surgical management and morbidity of pediatric magnet ingestions. J Surg Res. 2015 Nov; 199(1):137-40. View Abstract

  74. Villin immunohistochemistry is a reliable method for diagnosing microvillus inclusion disease. Am J Surg Pathol. 2015 Feb; 39(2):245-50. View Abstract

  75. Functional significance of single nucleotide polymorphisms in the lactase gene in diverse US patients and evidence for a novel lactase persistence allele at -13909 in those of European ancestry. J Pediatr Gastroenterol Nutr. 2015 Feb; 60(2):182-91. View Abstract

  76. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm Bowel Dis. 2015 Feb; 21(2):307-14. View Abstract

  77. Efficacy of oral methotrexate in paediatric Crohn's disease: a multicentre propensity score study. Gut. 2015 Dec; 64(12):1898-904. View Abstract

  78. Predictors of abdominal pain in depressed pediatric inflammatory bowel disease patients. Inflamm Bowel Dis. 2014 Aug; 20(8):1329-40. View Abstract

  79. Benefit/risk assessment of biologic monotherapy vs combination therapy in Crohn's Remains Challenging. Gastroenterology. 2014 Aug; 147(2):540. View Abstract

  80. Pediatric ulcerative colitis: a practical guide to management. Paediatr Drugs. 2014 Jun; 16(3):189-98. View Abstract

  81. The effect of immunomodulators and biologics on indication for surgical bowel resection in children with Crohn's disease. Inflamm Bowel Dis. 2014 Jun; 20(6):1015-20. View Abstract

  82. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y). 2014 Jun; 10(6):355-63. View Abstract

  83. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry. 2014 Jul; 53(7):726-35. View Abstract

  84. Authors' response. J Pediatr Gastroenterol Nutr. 2014 May; 58(5):e51. View Abstract

  85. Predictors of depression in youth with Crohn disease. J Pediatr Gastroenterol Nutr. 2014 May; 58(5):569-73. View Abstract

  86. Depression subtypes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2014 May; 58(5):574-81. View Abstract

  87. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. BMC Gastroenterol. 2014 Apr 09; 14:71. View Abstract

  88. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb; 58(3):309-18. View Abstract

  89. Advocating for child health: how the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition took action against high-powered magnets. J Pediatr. 2014 Jan; 164(1):4-5.e1. View Abstract

  90. NASPGHAN single-topic symposium: discovering the future of pediatric IBD care. J Pediatr Gastroenterol Nutr. 2014 Jan; 58(1):130-8. View Abstract

  91. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb; 58(3):e44-100. View Abstract

  92. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013 Sep; 57(3):343-7. View Abstract

  93. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013 Sep; 57(3):293-7. View Abstract

  94. Characterization of relations among sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn disease. J Pediatr Gastroenterol Nutr. 2013 Sep; 57(3):335-42. View Abstract

  95. Predictive value of the Pediatric Ulcerative Colitis Activity Index in the surgical management of ulcerative colitis. J Pediatr Surg. 2013 Jul; 48(7):1540-5. View Abstract

  96. Characterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease. PLoS One. 2013; 8(6):e63686. View Abstract

  97. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jun; 19(7):1441-9. View Abstract

  98. The overlap of functional abdominal pain in pediatric Crohn's disease. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):826-31. View Abstract

  99. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum. Expert Rev Clin Immunol. 2013 Feb; 9(2):117-27. View Abstract

  100. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013 Jan; 56(1):12-8. View Abstract

  101. Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease. J Int Neuropsychol Soc. 2013 Jan; 19(1):96-109. View Abstract

  102. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr. 2012 Sep; 55(3):239-42. View Abstract

  103. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. J Clin Psychol Med Settings. 2012 Sep; 19(3):329-37. View Abstract

  104. Characterization of fast and slow diffusion from diffusion-weighted MRI of pediatric Crohn's disease. J Magn Reson Imaging. 2013 Jan; 37(1):156-63. View Abstract

  105. Budesonide use in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012 Aug; 55(2):200-4. View Abstract

  106. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012 Sep; 107(9):1399-406. View Abstract

  107. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One. 2012; 7(6):e39242. View Abstract

  108. An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc. 2013 Jan 01; 20(1):172-9. View Abstract

  109. Using the Children's Depression Inventory in youth with inflammatory bowel disease: support for a physical illness-related factor. Compr Psychiatry. 2012 Nov; 53(8):1194-9. View Abstract

  110. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012 Apr 16; 13(9):R79. View Abstract

  111. Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012 May; 18(5):935-42. View Abstract

  112. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis. 2012 May; 18(5):838-43. View Abstract

  113. "Tac"kling a difficult problem: using tacrolimus to maintain remission in ulcerative colitis. J Clin Gastroenterol. 2011 Jul; 45(6):479-80. View Abstract

  114. Agreement between patient- and physician-completed Pediatric Ulcerative Colitis Activity Index scores. J Pediatr Gastroenterol Nutr. 2011 Jun; 52(6):708-13. View Abstract

  115. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011 Apr; 106(4):574-88. View Abstract

  116. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011 May; 106(5):981-7. View Abstract

  117. Innate and adaptive immune connections in inflammatory bowel diseases. Curr Opin Gastroenterol. 2010 Nov; 26(6):572-7. View Abstract

  118. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011 Jan; 17(1):22-9. View Abstract

  119. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010 Aug; 51(2):140-5. View Abstract

  120. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul; 6(4):659-66. View Abstract

  121. Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol. 2010 Sep; 8(9):789-94. View Abstract

  122. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr. 2010 May; 50(5):562-5. View Abstract

  123. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010 Jun; 105(6):1430-6. View Abstract

  124. Probiotic for new onset ulcerative colitis in children: baby's got bac(teria). Inflamm Bowel Dis. 2010 Jan; 16(1):177-8. View Abstract

  125. Monitoring Disease Activity in Pediatric IBD Patients (monograph). Children's Digestive Health and Nutrition Foundation 2009 . 2010.

  126. Healthcare burden of inflammatory bowel disease in the United States: more than pain and diarrhea. Inflamm Bowel Dis. 2009 Nov; 15(11):1767-8. View Abstract

  127. Restorative proctocolectomy and ileal pouch-anal anastomosis in children. Dis Colon Rectum. 2009 Sep; 52(9):1645-9. View Abstract

  128. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009 Sep; 15(9):1417-23. View Abstract

  129. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2009 Sep; 49(3):297-303. View Abstract

  130. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009 Aug; 15(8):1218-23. View Abstract

  131. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009 Jun; 15(6):816-22. View Abstract

  132. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. Inflamm Bowel Dis. 2009 Mar; 15(3):383-7. View Abstract

  133. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009 Feb; 48(2):168-74. View Abstract

  134. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009 Feb; 104(2):444-53. View Abstract

  135. Making the right diagnosis: differentiating between Crohn disease and ulcerative colitis in children and young adults. . 2009.

  136. Approach to clinical diagnosis of inflammatory bowel disease. In: Walker-Smith JA, Lebenthal E, Branski D. Pediatric Inflammatory Bowel Disease: Perspective and consequences. 2009; 123-137.

  137. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res. 2008 Aug; 52(8):867-74. View Abstract

  138. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. 2008 Jul; 14(7):949-54. View Abstract

  139. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008 Apr; 20(4):269-84. View Abstract

  140. Research and clinical challenges in paediatric inflammatory bowel disease. Dig Liver Dis. 2008 Jan; 40(1):32-8. View Abstract

  141. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry. 2007 Oct; 46(10):1290-1298. View Abstract

  142. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007 Dec; 5(12):1424-9. View Abstract

  143. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr. 2007 Nov; 151(5):523-7. View Abstract

  144. Challenges and progress in pediatric inflammatory bowel disease. Curr Opin Gastroenterol. 2007 Jul; 23(4):406-12. View Abstract

  145. Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis. 2007 Jul; 13(7):890-5. View Abstract

  146. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007 Jun; 119(6):1113-9. View Abstract

  147. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007 May; 44(5):653-74. View Abstract

  148. Pete Learns About Crohn's and Colitis. 2007.

  149. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J Pediatr Surg. 2007 Jan; 42(1):31-4; discussion 34-5. View Abstract

  150. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006 Dec; 12(12):1101-6. View Abstract

  151. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006 Sep; 12(9):885-913. View Abstract

  152. Health-related quality of life in the first year after a diagnosis of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006 Aug; 12(8):684-91. View Abstract

  153. Effective advocacy for patients with inflammatory bowel disease: communication with insurance companies, school administrators, employers, and other health care overseers. Inflamm Bowel Dis. 2006 Aug; 12(8):814-23. View Abstract

  154. Medical therapy for refractory pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2006 Oct; 4(10):1199-213. View Abstract

  155. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006 Sep; 4(9):1124-9. View Abstract

  156. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006 Sep; 4(9):1118-23. View Abstract

  157. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006 Apr; 12(4):251-7. View Abstract

  158. Gastrointestinal issues in developmentally disabled children. LI Rubin and AC Crocker eds. Medical Care for children and adults with developmental disabilities. 2006; 307-324.

  159. Current therapy of inflammatory bowel disease in children. Paediatr Drugs. 2006; 8(5):279-302. View Abstract

  160. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005 Oct; 41(4):416-21. View Abstract

  161. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005 Sep; 11(9):833-9. View Abstract

  162. Workshop report: prevention of postoperative recurrence in Crohn's disease. J Pediatr Gastroenterol Nutr. 2005 Aug; 41(2):145-51. View Abstract

  163. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm Bowel Dis. 2005 Jun; 11(6):519-27. View Abstract

  164. Normal homocysteine levels in a population of children with inflammatory bowel disease. Inflamm Bowel Dis. 2005 Jun; 11(6):620-1. View Abstract

  165. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis. 2005 Feb; 11(2):185-96. View Abstract

  166. Probiotic Therapies: the crossroads of traditional and alternative medicine. Practical Gastroenterology. 2005; 4:20-36.

  167. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004 Nov; 99(11):2235-41. View Abstract

  168. Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr. 2004 Oct; 39(4):395-403. View Abstract

  169. Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill? Inflamm Bowel Dis. 2004 Jul; 10(4):481-3. View Abstract

  170. Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. Am J Surg Pathol. 2004 Feb; 28(2):190-7. View Abstract

  171. Gastroenterology questions for the American Academy of Pediatrics PREP course. Available on www.pedialink.org. 2004.

  172. Immunosuppressive therapies. Walker WA, Goulet O, Kleinman R, Sherman P, Shneider B, Sanderson I eds. Pediatric Gastrointestinal Disease. 2004; 2:2015-2044.

  173. Pediatric Crohn's disease. Johnson L ed. Encyclopedia of Gastroenterology. 2004; 520-527.

  174. Ulcerative colitis. Guandalini ed, Textbook of Pediatric Gastroenterology. 2004; 385-418.

  175. Gastroenterologic and Liver Disorders. Stiehm ER, Ochs H, Winkelstein J eds. Immunologic disorders in infants and children. 2004; 1055-1102.

  176. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003 Dec; 98(12):2712-8. View Abstract

  177. Blocking lymphocyte adhesion: new treatment for sticky cases of Crohn disease? J Pediatr Gastroenterol Nutr. 2003 Aug; 37(2):211-3. View Abstract

  178. Isolated neonatal swallowing dysfunction: a case series and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):30-5. View Abstract

  179. Nutritional therapy of inflammatory bowel disease. Caballero B, Trugo L, Finglas P eds. Encyclopedia of Food Sciences and Nutrition. 2003; 3315-3320.

  180. Webcast: Crohn's and colitis Foundation - Management of IBD in special populations. Available on www.ccfa.org. 2003.

  181. Feeding tubes. Puder M, Hansen A eds. Manual of Neonatal Surgical Care. 2003; 303-314.

  182. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002 Nov; 47(11):2625-34. View Abstract

  183. Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2002 Nov; 35(5):695-9. View Abstract

  184. Blame Canada: growing questions about budesonide. Inflamm Bowel Dis. 2002 May; 8(3):235. View Abstract

  185. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol. 2002 Feb; 97(2):382-8. View Abstract

  186. Research agenda for pediatric gastroenterology, hepatology and nutrition: chronic inflammatory bowel disease. Report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for the Children's Digestive Health and Nutrition Foundation. J Pediatr Gastroenterol Nutr. 2002; 35 Suppl 3:S286-90. View Abstract

  187. Board review questions in pediatric gastroenterology for the American Academy of Pediatrics PREP the course. 16 Questions per year for 6 years (2002-2008). 2002.

  188. Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001 Nov; 33(5):548-53. View Abstract

  189. Inflammatory bowel disease associated with immune thrombocytopenic purpura in children. J Pediatr Gastroenterol Nutr. 2001 Nov; 33(5):582-7. View Abstract

  190. Multiple micronutrient deficiencies in a child fed an elemental formula. J Pediatr Gastroenterol Nutr. 2001 Nov; 33(5):602-5. View Abstract

  191. Abdominal migraine in children with neurofibromatosis type 1: a case series and review of gastrointestinal involvement in NF1. J Pediatr Gastroenterol Nutr. 2001 Aug; 33(2):149-54. View Abstract

  192. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001 Jan; 120(1):13-20. View Abstract

  193. Thalidomide in gastrointestinal disorders. Drugs. 2001; 61(6):777-87. View Abstract

  194. Epidemiology and diagnosis of inflammatory bowel disease. Bonis ed., Up to Date. 2001; 9.

  195. The spectrum of pediatric gastroesophageal reflux. JAMA. 2000 Dec 27; 284(24):3125-6. View Abstract

  196. Oral tacrolimus treatment of severe colitis in children. J Pediatr. 2000 Dec; 137(6):794-9. View Abstract

  197. Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children. Dig Dis Sci. 1999 Dec; 44(12):2500-7. View Abstract

  198. Allergic esophagitis in children: a clinicopathological entity. Am J Surg Pathol. 1999 Apr; 23(4):390-6. View Abstract

  199. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci. 1999 Feb; 44(2):424-30. View Abstract

  200. Gastrointestinal Manifestations of Primary Immunodeficiencies. Wyllie R, Hyams JS. Pediatric Gastrointestinal Disease. 1999; 381-389.

  201. Crohn's disease in children and adolescents. Bonis ed, Up to Date (CD-ROM). 1999; 8.

  202. Ulcerative Colitis in children and adolescents. Bonis ed, Up to Date (CD-ROM). 1999.

  203. Gastrointestinal issues in the child with developmental disabilities. International Seminars in Pediatric Gastroenterology and Nutrition. 1999; 8:1-9.

  204. Intraduodenal hematoma complicating intestinal biopsy: case reports and review of the literature. Am J Gastroenterol. 1998 Dec; 93(12):2547-50. View Abstract

  205. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med. 1998 Nov; 152(11):1132-6. View Abstract

  206. Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis. Pediatr Pulmonol. 1998 Nov; 26(5):365-9. View Abstract

  207. Serum leptin in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998 May; 26(5):500-5. View Abstract

  208. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr. 1998 Feb; 26(2):129-35. View Abstract

  209. Clinical outcome of ulcerative proctitis in children. J Pediatr Gastroenterol Nutr. 1997 Aug; 25(2):149-52. View Abstract

  210. Preventing relapse after surgery for Crohn's disease: where do we go from here? J Pediatr Gastroenterol Nutr. 1997 Jul; 25(1):114-5. View Abstract

  211. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes. Dig Dis Sci. 1997 Jul; 42(7):1542-8. View Abstract

  212. Serum basic fibroblast growth factor in pediatric Crohn's disease. Implications for wound healing. Dig Dis Sci. 1997 Feb; 42(2):378-86. View Abstract

  213. Gastroenterologic Disorders. Graef J, Priebe C eds. Manual of Pediatric Therapeutics. 1997.

  214. Immunosuppressive Agents in Gastrointestinal Disease. Kresina T, ed. Manual of Immune Modulating Agents. 1997.

  215. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr. 1996 Oct; 23(3):329-33. View Abstract

  216. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J Pediatr Gastroenterol Nutr. 1996 Aug; 23(2):164-71. View Abstract

  217. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology. 1996 Jul; 111(1):237-43. View Abstract

  218. Immunology and Gastrointestinal Disease. Stiehm ER ed, Immunologic Disorders of Infants and Children. 1995; 697-741.

  219. Immunosuppressive Agents in Gastrointestinal Disease. Current Opinion in Gastroenterology. 1995; 11:554-561.

  220. Immunosuppressive therapies in Pediatric Gastroenterology. Walker WA, Hamilton JR, Watkins JB, Walker-Smith JA, Durie PR. Pediatric Gastrointestinal Disease. 1995.

  221. New immunotherapies and their potential for treatment of inflammatory bowel disease. Progress in Inflammatory Bowel Disease. 1993; 14:6-11.

  222. Immunology and Gastrointestinal Disease. Wyllie R and Hyams J eds., Pediatric Gastrointestinal Disease. 1993; 64-73.

  223. Basic gastrointestinal immunology. Bouchier IA, Hodgson HJ, Keighley MR eds., Gastroenterology: Clinical Science and Practice. 1993; 577-582.

  224. Ringed esophagus: an association with esophagitis. Am J Gastroenterol. 1992 Sep; 87(9):1187-90. View Abstract

  225. Development of the Intestinal Mucosal Barrier. McDonald TT ed, Ontogeny of the Immune System of the Gut. 1991.

  226. Diarrhea in the Immunodeficient Host. Rudolph's Textbook of Pediatrics. 1991; 1012-1015.

  227. Abdominal Wall Defects. Rudolph Textbook of Pediatrics. 1991; 1040-1042.

  228. Imaging of neuroblastoma: an overview. Pediatr Radiol. 1986; 16(2):89-106. View Abstract

  229. Monoclonal antibody phenotyping of B-cell non-Hodgkin's lymphomas. The Southeastern Cancer Study Group experience. Am J Pathol. 1985 Dec; 121(3):514-21. View Abstract

Medicine combines science with art and knowledge with compassion. I followed my father's footsteps and became a physician because I saw how rewarding his career was (he still practices medicine at age 86). By working at Boston Children's Hospital, I not only get to help people day to day, but am also able to participate in studies that will help us find the causes and cures of Inflammatory Bowel Disease.

BESbswy
BESbswy